Polymyxin B3-Tobramycin Hybrids with Pseudomonas aeruginosa-Selective Antibacterial Activity and Strong Potentiation of Rifampicin, Minocycline, and Vancomycin

ACS Infectious Diseases

Volumn 3, Issue 12, 2017, Pages 941-954

  Domalaon, Ronald ^a   Yang, Xuan ^a   Lyu, Yinfeng ^a,c   Zhanel, George G ^b   Schweizer, Frank ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c NORTHEAST AGRICULTURAL UNIVERSITY   (China)

Author keywords

adjuvant; antimicrobial hybrid; polymyxin; Pseudomonas aeruginosa; rifampicin; tobramycin

Indexed keywords

CARBAPENEM; CHLORAMPHENICOL; CLINDAMYCIN; DOXYCYCLINE; IMIPENEM; LINEZOLID; MEROPENEM; MINOCYCLINE; NOVOBIOCIN; POLYMYXIN B3; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; TIGECYCLINE; TOBRAMYCIN; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; POLYMYXIN;

ACINETOBACTER BAUMANNII; ADJUVANT THERAPY; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COVALENT BOND; CYCLOADDITION; DRUG CONJUGATION; DRUG POTENTIATION; DRUG SYNTHESIS; KLEBSIELLA PNEUMONIAE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; DRUG EFFECT; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; POLYMYXINS; PSEUDOMONAS AERUGINOSA; RIFAMPIN; TOBRAMYCIN; VANCOMYCIN;

EID: 85033796462     PISSN: None     EISSN: 23738227     Source Type: Journal    
DOI: 10.1021/acsinfecdis.7b00145     Document Type: Article

References (48)

1. de Smalen, A. W., Ghorab, H., Abd El Ghany, M., and Hill-Cawthorne, G. A. (2017) Refugees and antimicrobial resistance: A systematic review Travel Med. Infect. Dis. 15, 23-28 10.1016/j.tmaid.2016.12.001
2. Ayukekbong, J. A., Ntemgwa, M., and Atabe, A. N. (2017) The threat of antimicrobial resistance in developing countries: Causes and control strategies Antimicrob. Resist. Infect. Control 6, 47 10.1186/s13756-017-0208-x
3. Brown, E. D. and Wright, G. D. (2016) Antibacterial drug discovery in the resistance era Nature 529 (7586) 336-343 10.1038/nature17042
4. Bartsch, S. M., McKinnell, J. A., Mueller, L. E., Miller, L. G., Gohil, S. K., Huang, S. S., and Lee, B. Y. (2017) Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States Clin. Microbiol. Infect. 23 (1) 48.e9-48.e16 10.1016/j.cmi.2016.09.003
5. Cooper, M. A. and Shlaes, D. (2011) Fix the antibiotics pipeline Nature 472 (7341) 32 10.1038/472032a
6. World Health Organization. (2017) Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics, http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/(accessed Jun 1, 2017).
7. Silver, L. L. A. (2016) Gestalt approach to Gram-negative entry Bioorg. Med. Chem. 24 (24) 6379-6389 10.1016/j.bmc.2016.06.044
8. Pokrovskaya, V. and Baasov, T. (2010) Dual-acting hybrid antibiotics: A promising strategy to combat bacterial resistance Expert Opin. Drug Discovery 5 (9) 883-902 10.1517/17460441.2010.508069
9. Parkes, A. L. and Yule, I. A. (2016) Hybrid antibiotics-clinical progress and novel designs Expert Opin. Drug Discovery 11 (7) 665-680 10.1080/17460441.2016.1187597
10. Klahn, P. and Bronstrup, M. (2017) Bifunctional antimicrobial conjugates and hybrid antimicrobials Nat. Prod. Rep. 34 (7) 832-885 10.1039/C7NP00006E
11. The PEW Charitable Trust. (2014) Antibiotics Currently in Clinical Development, http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development (accessed Jun 1, 2017).
12. Katsube, T., Echols, R., Arjona Ferreira, J. C., Krenz, H. K., Berg, J. K., and Galloway, C. (2017) Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: Pharmacokinetics and safety in subjects with renal impairment J. Clin. Pharmacol. 57 (5) 584-591 10.1002/jcph.841
13. Endres, B. T., Basseres, E., Alam, M. J., and Garey, K. W. (2017) Cadazolid for the treatment of Clostridium difficile Expert Opin. Invest. Drugs 26 (4) 509-514 10.1080/13543784.2017.1304538
14. Gorityala, B. K., Guchhait, G., Fernando, D. M., Deo, S., McKenna, S. A., Zhanel, G. G., Kumar, A., and Schweizer, F. (2016) Adjuvants based on hybrid antibiotics overcome resistance in Pseudomonas aeruginosa and enhance fluoroquinolone efficacy Angew. Chem., Int. Ed. 55 (2) 555-559 10.1002/anie.201508330
15. Gorityala, B. K., Guchhait, G., Goswami, S., Fernando, D. M., Kumar, A., Zhanel, G. G., and Schweizer, F. (2016) Hybrid antibiotic overcomes resistance in P. aeruginosa by enhancing outer membrane penetration and reducing efflux J. Med. Chem. 59 (18) 8441-8455 10.1021/acs.jmedchem.6b00867
16. Yang, X., Goswami, S., Gorityala, B. K., Domalaon, R., Lyu, Y., Kumar, A., Zhanel, G. G., and Schweizer, F. (2017) A tobramycin vector enhances synergy and efficacy of efflux pump inhibitors against multidrug-resistant Gram-negative bacteria J. Med. Chem. 60 (9) 3913-3932 10.1021/acs.jmedchem.7b00156
17. Lyu, Y., Yang, X., Goswami, S., Gorityala, B. K., Idowu, T., Domalaon, R., Zhanel, G. G., Shan, A., and Schweizer, F. (2017) Amphiphilic tobramycin-lysine conjugates sensitize multidrug resistant Gram-negative bacteria to rifampicin and minocycline J. Med. Chem. 60 (9) 3684-3702 10.1021/acs.jmedchem.6b01742
18. Hancock, R. E. (1981) Aminoglycoside uptake and mode of action-with special reference to streptomycin and gentamicin. II. Effects of aminoglycosides on cells J. Antimicrob. Chemother. 8 (6) 429-445 10.1093/jac/8.6.429
19. Berkov-Zrihen, Y., Herzog, I. M., Benhamou, R. I., Feldman, M., Steinbuch, K. B., Shaul, P., Lerer, S., Eldar, A., and Fridman, M. (2015) Tobramycin and nebramine as pseudo-oligosaccharide scaffolds for the development of antimicrobial cationic amphiphiles Chem.-Eur. J. 21 (11) 4340-4349 10.1002/chem.201406404
20. Shaul, P., Benhamou, R. I., Herzog, I. M., Louzoun Zada, S., Ebenstein, Y., and Fridman, M. (2016) Synthesis and evaluation of membrane permeabilizing properties of cationic amphiphiles derived from the disaccharide trehalose Org. Biomol. Chem. 14 (11) 3012-3015 10.1039/C6OB00031B
21. Sautrey, G., Zimmermann, L., Deleu, M., Delbar, A., Souza Machado, L., Jeannot, K., Van Bambeke, F., Buyck, J. M., Decout, J.-L., and Mingeot-Leclercq, M.-P. (2014) New amphiphilic neamine derivatives active against resistant Pseudomonas aeruginosa and their interactions with lipopolysaccharides Antimicrob. Agents Chemother. 58 (8) 4420-4430 10.1128/AAC.02536-13
22. Sautrey, G., El Khoury, M., Dos Santos, A. G., Zimmermann, L., Deleu, M., Lins, L., Decout, J.-L., and Mingeot-Leclercq, M.-P. (2016) Negatively Charged Lipids as a Potential Target for New Amphiphilic Aminoglycoside Antibiotics: A BIOPHYSICAL STUDY J. Biol. Chem. 291 (26) 13864-13874 10.1074/jbc.M115.665364
23. Dhondikubeer, R., Bera, S., Zhanel, G. G., and Schweizer, F. (2012) Antibacterial activity of amphiphilic tobramycin J. Antibiot. 65 (10) 495-498 10.1038/ja.2012.59
24. Zimmermann, L., Das, I., Desire, J., Sautrey, G., Barros R S, V., El Khoury, M., Mingeot-Leclercq, M.-P., and Decout, J.-L. (2016) New broad-spectrum antibacterial amphiphilic aminoglycosides active against resistant bacteria: From neamine derivatives to smaller neosamine analogues J. Med. Chem. 59 (20) 9350-9369 10.1021/acs.jmedchem.6b00818
25. Bera, S., Dhondikubeer, R., Findlay, B., Zhanel, G. G., and Schweizer, F. (2012) Synthesis and antibacterial activities of amphiphilic neomycin B-based bilipid conjugates and fluorinated neomycin B-based lipids Molecules 17 (8) 9129-9141 10.3390/molecules17089129
26. Bera, S., Zhanel, G. G., and Schweizer, F. (2010) Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity J. Med. Chem. 53 (9) 3626-3631 10.1021/jm1000437
27. Bera, S., Zhanel, G. G., and Schweizer, F. (2010) Antibacterial activity of guanidinylated neomycin B- A nd kanamycin A-derived amphiphilic lipid conjugates J. Antimicrob. Chemother. 65 (6) 1224-1227 10.1093/jac/dkq083
28. Bera, S., Zhanel, G. G., and Schweizer, F. (2008) Design, synthesis, and antibacterial activities of neomycin-lipid conjugates: Polycationic lipids with potent Gram-positive activity J. Med. Chem. 51 (19) 6160-6164 10.1021/jm800345u
29. Udumula, V., Ham, Y. W., Fosso, M. Y., Chan, K. Y., Rai, R., Zhang, J., Li, J., and Chang, C.-W. T. (2013) Investigation of antibacterial mode of action for traditional and amphiphilic aminoglycosides Bioorg. Med. Chem. Lett. 23 (6) 1671-1675 10.1016/j.bmcl.2013.01.073
30. Guchhait, G., Altieri, A., Gorityala, B., Yang, X., Findlay, B., Zhanel, G. G., Mookherjee, N., and Schweizer, F. (2015) Amphiphilic tobramycins with immunomodulatory properties Angew. Chem., Int. Ed. 54 (21) 6278-6282 10.1002/anie.201500598
31. Lenhard, J. R., Nation, R. L., and Tsuji, B. T. (2016) Synergistic combinations of polymyxins Int. J. Antimicrob. Agents 48 (6) 607-613 10.1016/j.ijantimicag.2016.09.014
32. Masuda, N., Sakagawa, E., Ohya, S., Gotoh, N., Tsujimoto, H., and Nishino, T. (2000) Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa Antimicrob. Agents Chemother. 44 (12) 3322-3327 10.1128/AAC.44.12.3322-3327.2000
33. Velkov, T., Thompson, P. E., Nation, R. L., and Li, J. (2010) Structure-activity relationships of polymyxin antibiotics J. Med. Chem. 53 (5) 1898-1916 10.1021/jm900999h
34. Velkov, T., Roberts, K. D., Nation, R. L., Thompson, P. E., and Li, J. (2013) Pharmacology of polymyxins: New insights into an "old" class of antibiotics Future Microbiol. 8 (6) 711-724 10.2217/fmb.13.39
35. Hanessian, S., Tremblay, M., and Swayze, E. E. (2003) Tobramycin analogues with C-5 aminoalkyl ether chains intended to mimic rings III and IV of paromomycin Tetrahedron 59 (7) 983-993 10.1016/S0040-4020(02)01624-1
36. Kanazawa, K., Sato, Y., Ohki, K., Okimura, K., Uchida, Y., Shindo, M., and Sakura, N. (2009) Contribution of each amino acid residue in polymyxin B(3) to antimicrobial and lipopolysaccharide binding activity Chem. Pharm. Bull. 57 (3) 240-244 10.1248/cpb.57.240
37. Orwa, J. A., Govaerts, C., Busson, R., Roets, E., Van Schepdael, A., and Hoogmartens, J. (2001) Isolation and structural characterization of colistin components J. Antibiot. 54 (7) 595-599 10.7164/antibiotics.54.595
38. Kassamali, Z., Prince, R. A., Danziger, L. H., Rotschafer, J. C., Rhomberg, P. R., and Jones, R. N. (2015) Microbiological assessment of polymyxin B components tested alone and in combination Antimicrob. Agents Chemother. 59 (12) 7823-7825 10.1128/AAC.01021-15
39. Tsubery, H., Ofek, I., Cohen, S., and Fridkin, M. (2000) Structure-function studies of polymyxin B nonapeptide: Implications to sensitization of gram-negative bacteria J. Med. Chem. 43 (16) 3085-3092 10.1021/jm0000057
40. Zhanel, G. G., DeCorby, M., Laing, N., Weshnoweski, B., Vashisht, R., Tailor, F., Nichol, K. a., Wierzbowski, A., Baudry, P. J., and Karlowsky, J. a. et al. 2008, Antimicrobial-resistant pathogens in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006 Antimicrob. Agents Chemother. 52 (4) 1430-1437 10.1128/AAC.01538-07
41. Hoban, D. J. and Zhanel, G. G. (2011) Introduction to the CANWARD Study (2007-2009) Diagn. Microbiol. Infect. Dis. 69, 289-290 10.1016/j.diagmicrobio.2010.10.024
42. Hurdle, J. G., O'Neill, A. J., Chopra, I., and Lee, R. E. (2011) Targeting bacterial membrane function: An underexploited mechanism for treating persistent infections Nat. Rev. Microbiol. 9 (1) 62-75 10.1038/nrmicro2474
43. The Clinical and Laboratory Standards Institute. ((2016) Performance Standards for Antimicrobial Susceptibility Testing CLSI supplement M100S, 26 th ed., Clinical and Laboratory Standards Institute, Wayne, PA.
44. Velkov, T., Deris, Z. Z., Huang, J. X., Azad, M. A. K., Butler, M., Sivanesan, S., Kaminskas, L. M., Dong, Y.-D., Boyd, B., and Baker, M. A. et al. 2014, Surface changes and polymyxin interactions with a resistant strain of Klebsiella pneumoniae Innate Immun. 20 (4) 350-363 10.1177/1753425913493337
45. Anaya-Lopez, J. L., Lopez-Meza, J. E., and Ochoa-Zarzosa, A. (2013) Bacterial resistance to cationic antimicrobial peptides Crit. Rev. Microbiol. 39 (2) 180-195 10.3109/1040841X.2012.699025
46. Poirel, L., Jayol, A., and Nordmann, P. (2017) Polymyxins: Antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes Clin. Microbiol. Rev. 30 (2) 557-596 10.1128/CMR.00064-16
47. Meletiadis, J., Pournaras, S., Roilides, E., and Walsh, T. J. (2010) Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumi Antimicrob. Agents Chemother. 54 (2) 602-609 10.1128/AAC.00999-09
48. Yamaguchi, A., Ohmori, H., Kaneko-Ohdera, M., Nomura, T., and Sawai, T. (1991) Delta pH-dependent accumulation of tetracycline in Escherichia coli Antimicrob. Agents Chemother. 35 (1) 53-56 10.1128/AAC.35.1.53